Concepedia

Publication | Open Access

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

DOIFull Paper Access

21

Citations

29

References

2023

Year

Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik‐Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen A. Burke,
Clinical Cancer Research

Abstract

Targeting both STAT3 and BTK in combination is safe and tolerable but efficacy is limited in R/R DLBCL. Results support evaluation of circulating tumor DNA as a biomarker for clinical response.

References

YearCitations

Page 1